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Demographic properties of the patients
Parameters
Patients who
died
Patients who
survived p
Male n (%) 15 (83,3) 89 (78,1) 0,612
Age (meanSD) 568 6010 0,049
LV EF (%) 242 274 <0,001
Duration of heart failure (year) 3,81,7 4,63,6 0,869
NYHA functional class, n (%) 13 (72,3) 38 (33,4) 0,001
Ischemic etiology of heart
failure, n (%)
8 (44,4) 80 (70,2) 0,031
Rervascularization, n (%) 7 (38,9) 61 (53,5) 0,249
CRT-D implantation, n (%) 6 (33,3) 29 (25,4) 0,481
Diabetes Mellitus n (%) 5 (27,8) 30 (26,3) 0,896
Hyperlipidemia, n (%) 4 (22,2) 56 (49,1) 0,033
Hypertension, n (%) 7 (38,9) 66 (57,9) 0,132
Smoking, n (%) 5 (27,8) 26 (22,8) 0,644
Family history, n (%) 3 (16,7) 9 (7,9) 0,229
Chronic obstructive lung
disease, n (%)
5 (%27,8) 21 (%18,4) 0,354
Chronic renal failure, n (%) 9 (%50) 30 (26,3) 0,041
Cerebrovascular event, n (%) 2 (%11,1) 6 (%5,3) 0,334
Hepatic dysfunction, n (%) 3 (%16,7) 4 (%3,5) 0,021
Anemia, n (%) 5 (%27,8) 20 (%17,5) 0,303
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Ssystolic and diastolic function are different in ischemic and non-ischemic cardiomy-
opathy depending on the underlying cause. In the present study, we aimed to inves-
tigate right ventricular volume, diameter and systolic function in ischemic and non-
ischemic cardiomyopathy by 2D, M mode, transvalvular Doppler and tissue Doppler
echocardiography.
Method: The study population consisted of 20 ischemic (ICMP) and 21 non-ischemic
dilated cardiomyopathy (NICMP) patients with reduced left ventricular function
(EF <%35), increased left ventricular end-diastolic diameter (LVEDD >5.5 cm),
sinus ritm, less than moderate valve disease. The volume, diameter and functions of
the right and left ventricle are assessed by echocardiography. According to ischemic
and non-ischemic cardiomyopathy groups, right ventricular structure and function
were compared by using correlation analysis.
Results: Patients left ventricular systolic and diastolic functions evaluated by 2D,
mitral ﬂow Doppler and tissue Doppler echocardiography were similar in both groups.
Right ventricular longitudinal diameter in ischemic CMP was signiﬁcantly lower
when compared with non-ischemic CMP (7.56 cm, 6.66 cm p¼0.001). Mean RVEF
was comparable between the groups and 59% in NICMP while 61% in ICMP
(p¼0,346). There were no signiﬁcant differences between the groups regarding right
ventricular tricuspid ﬂow Doppler parameters. In tissue Doppler parameters, RV
lateral annulus Sm velocity was signiﬁcantly lower in ICMP than NICMP (0.11 cm/sn
vs 0.09 cm/sn; p¼0.007). TAPSE values was signiﬁcantly lover in the ICMP group
(2.29 and 2.02 p¼0.024).The other parameters assessed by tissue Doppler echocar-
diography were comparable between the groups.
Conclusıon: Reduction in right ventricular function might be different due to
hemodynamic deterioration, right ventricular infarction and also involvement of right
ventricular myopathic changes. The present study results revealed that right ventric-
ular function was signiﬁcantly decreased in ischemic heart failure when compared to
the non-ischemic group.
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Objectıve: The prognostic value of right ventricular function in heart failure is well
known. In our study, we aimed to investigate the relation of right ventricular stroke
work index (RV SWI), an invasive hemodynamic parameter of right ventricle with
prognosis of heart failure and cardiac events.
Materıals-Methods: The study followed up 132 patients admitted to our hospital
outpatient clinic between April 2011 - November 2012 with diagnosis of advanced
stage heart failure, (104 male, 28 female and age 24-81 years). The ﬁles of patients
were searched retrospectively and patients called by phone for ascertain of prognosis.
All patients’ medical history, demographic characteristics, cardiovascular risk factors,
comorbid illnesses, New York Heart Association functional class, echocardiographic
evaluations and basal right heart catheterizations performed were detected. The rela-
tion of RV SWI values with ventricular assist device insertion, heart transplantation,
cardiac resyncronisation therapy, rehospitalisation due to decompansation composite
end-points and with mortality were evaluated. Advanced stage heart failure was
deﬁned as ejection fraction < 35% with symptoms and/or signs of heart failure.
Results: In our study, 34 of 132 patients needed to rehospitalization due to cardiac
decompansation. Of these patients, 14 have died. In the patients with cardiac
decompensation right ventricular"stroke work index" 6.12.5 gr/m2/beat and 8.53.4
gr/m2/beat in the group without decompensation. Ischemic heart failure ethiology in
patients with cardiac decompensation were less frequently (p¼0.035), smoking rates
were higher (p¼0.006) and concomitant diseases were more frequently (p<0.05) than
of patients without cardiacdecompansition. Medication using frequency were signif-
icantly lower in the group with cardiac decompensation than without decom-
pansion.During 20 months follow-up, total mortality was observed in 18 (13.6%)
patients. The relation between RV SWI and mortality did not reach statistical
signiﬁcance (p¼0.773). In patients who died, mean RV SWI value was 7.53.4 g/m2/
beat, those who survived had RV SWI mean value 8.03.4 gr/m2/beat. The left
ventricular ejection fraction (p<0.001) and right ventricle systolic diameter (p<0.001)
had statistically signiﬁcant relation with mortality. In patients who survived without
cardiac events RV SWI value was signiﬁcantly different from those who survived with
cardiac events (p¼0.003), indicating that decreased RV SWI is associated with
increased cardiac event rates among patients with advanced stage heart failure.
Conclusıon: Right ventricular stroke work index is a predictor of event free survival
among patients with advanced stage heart failure. Our study did not support RV SWI
as single parameter of predictor of mortality. Risk models consisting of invasive, non-
invasive and clinical parameters should be developed for prediction of all-cause
mortality in advanced stage heart failure.C106 JACC VoPP-063
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Infusion: A Comparative Study with b Blocker Therapy
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Purpose: Ivabradine is a novel heart rate (HR) lowering agent acting by inhibiting the
If current in the sino-atrial node and has been shown to improve clinical outcomes in
chronic heart failure (HF). Inotropic stimulation with dobutamine (DOB) has been
known to increase HR and the incidence of cardiac arrhythmias in patients with HF.
However, the effects of ivabradine speciﬁcally on cardiac arrhythmias are unknown.
In this prospective study, we compared the effects of ivabradine treatment with
b blocker therapy on the increase in HR and incidence of ventricular arrhythmias
during DOB infusion using holter monitoring.
Methods: Sixty nine patients with acute decompensated HF requiring inotropic
support, LVEF <35% and in sinus rhythm were included in the present study. All
patients underwent holter recording for 6 h before the initiation of DOB infusion.
Following baseline recording, DOB was administered at incremental doses of 5, 10
and 15 mgr/kg/min, with 6-h steps. Holter monitoring was continued during 18 h of
DOB infusion. Ivabradine 7.5 mg was given at the initiation of DOB and read-
ministered at 12 h of DOB infusion in 26 patients not receiving b blocker therapy
(ivabradine group). 15 patients under b blocker therapy (b blocker group) and 28
patients not taking b blocker therapy (control group) did not receive ivabradine during
DOB infusion. Holter recordings were analyzed for change in HR, the median number
of ventricular premature contractions (VPC), ventricular couplets, episodes of non
sustained ventricular tachycardia (NSVT) and total ventricular arrhythmia for each
step of study protocol.
Results:Mean HR gradually and signiﬁcantly increased at each step of DOB infusion
in both control (8111, 9016, 9714 and 10116 respectively, p¼0.001) and
b blocker groups (7513, 8213, 8614 and 8813 respectively, p¼0.001), while
no signiﬁcant increase in HR was observed in ivabradine group (8217, 8215,
8514 and 8312 respectively, p¼0.439). The median number of VPCs, ventricular
couplets and total ventricular arrhythmia signiﬁcantly increased in ivabradine group
(p<0.001, p<0.003 and p<0.015, respectively). In control group, VPCs and total
ventricular arrhythmia increased signiﬁcantly (p<0.01 and p<0.018, respectively).
However, in b blocker group, no statistically signiﬁcant increase was found in VPCs,
couplets and total ventricular arrhythmias (Table). The incidence of NSVT did not
signiﬁcantly change in three groups.
Conclusıons: Ivabradine effectively prevents HR increase during DOB infusion,
however, it has almost no effect on DOB-induced ventricular arrhythmias. In contrast,
b blocker therapy fails to blunt DOB-induced increase in HR, but it prevents DOB-
induced increase in ventricular arrhythmias.l 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/POSTERS
Cardiac arrhythmias during dobutamine infusion
VPCs
Control
VPCs
Ivabradine
VPCs
B blocker
Total
Arrhythmia
Control
Total
Arrhythmia
Ivabradin
Total
Arrhythmia
B blocker
Baseline 149
(42-340)
132
(23-271)
45
(7-245)
128
(42-322)
158
(48-312)
49
(7-249)
DOB
5 mg/
kg/min
256
(55-508)
147
(30-538)
22
(11-448)
258
(58-469)
205
(55-722)
38
(11-565)
DOB
10 mg/
kg/min
251
(57-549)
158
(47-588)
96
(7-820)
241
(59-446)
226
(112-739)
99
(7-900)
DOB
15 mg/
kg/min
208
(44-446)
198
(47-503)
123
(21-634)
212
(45-438)
261
(74-493)
135
(21-847)
p 0.01 0.001 0.112 0.018 0.015 0.127
Table 1. Some characteristics of HF patients
Age (mean) 61.7011.75
Gender (m/f) 30 / 17
BMI 28.07
HT 21 (%44.7)
HLP 35 (%74.5)
DM 29 (%61.7)
LVEF (all HF group's average) %30.4010.4
SVEF (LVD group) %26.667.19
PEF-KY (n) 8 (%17)
DEF-KY (n) 39 (%83)
HF: Heart failure, BMI: body mass index, HT: hypertension, HLP: hyperlipidemia, DM: diabetes
mellitus LVEF: left ventricle ejection fraction LVD: left ventricle dysfunction, PEF: preserved
ejection fraction LEF: low ejection fraction
Table 2. miRNA expression fold changes
According to the normal
at admission
According to the normal
at discharge
miR- 22 - 2.39 f - 1.23 f
miR- 24 - 2.07 f - 1.59 f
miR- 92b + 2.33 f + 3.0 f
miRNA (miR): microribonucleic acid
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Introductıon: The new generation continuous-ﬂow left ventricle assist devices
(LVAD) is an option for heart transplantation for end-stage heart failure. These kind of
devices which developped with new technology, are implanted widely all over the
world for bridge to transplantation as well as destination therapy. The effect of LVAD
therapy on pulmonary artery pressure (PAP) in patients with ﬁxed pulmonary artery
hypertension (PAH) who are not good candidate for heart transplant, is an important
research topic. In this study, we evaluated the course of PAP in LVAD therapy and its
effect to post-transplant results.
Materıals-Methods: Between December 2008 and June 2013, continuous-ﬂow-
LVAD implantation were performed in 73 patients. Mean age was 48.39 years and
87% was male. The common etiology for heart failure was Idiopathic dilated
cardiomyopathy (69%). 9 of 73 patients (12,3%) were succesfully bridged to trans-
plantation. 8 patients with ﬁxed PAH were included in this study. PAP levels were
retrospectively compared before LVAD, after LVAD and after heart transplantion.
Results: Mean PAP before LVAD,after LVAD therapy and after heart transplant was
respectively 59,6 mmHg,34.8mmHg and 32.8mmHg. The reduction of PAP was
evident in patients supported with LVAD more than 60 days and consequently
complications related to PAH were lower in this group. Two patients were died in
early period of after heart transplant, the common feature of them was short support
time after LVAD. Mean support time was 34 days. PAP was still high after LVAD and
the main cause of mortality was right heart failure related multi-organ failure.
Conclusıon: The study is limited due to low-number of patients. But the decline of
ﬁxed PAH even it is refractory to vasodilator therapy was found in our analysis. As
a conclusion we think that LVAD therapy before heart transplantation, in patients
with decompansated heart failure and severe PAH, improves the results of heart
transplantation.
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Aim: The relationship of miRNA levels in patients admitted to the hospital because of
acute decompensated heart failure (ADHF) as cause of heart failure, in hospital and
short-term cardiovascular events, hospital readmission and mortality.
Method: Our study included 47 patients with decompansated HF (10 non-ischemic
and 37 ishemic origin) and 30 healty subjects (mean age: 57.138.32, %46.6 men).
Peripheral blood was withdrawn and kept under appropriate circumstances to evaluate
miR-22, miR-24 and miR-92b levels. When sample collection was completed, the
levels of mRNA detected from peripheral blood cells (leukocytes) were calculated
using the method PCR. The fold differences between groups were calculated as
average and miRNA6Ct(the amount of normalized miRNA in a cycle) values were
used for comparison.JACC Vol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/POSTResults: %63.8 of the patients were male and mean age was 61.7011.75. 39 patient
had left ventricular systolic dysfunction and the average LVEF was %26.667.19. All
patients', in-hospital mortality was %6.3, 1-month mortality rate was %4.5 and in this
duration hospital readmission rate was %31.8. There was a signiﬁcant fold change (>2
fold) between the patients miR-22, miR-24 and miR-92b levels and the control group.
However, the signiﬁcant changes in miRNA, both in low and preserved left ventricular
systolic function or in terms of etiology of HF showed no difference. Similarly, there
was no correlation between the6Ct values in terms of in-hospital and short-term
cardiovascular endpoints.
Conclusıon: Although there was a signiﬁcant fold change in miRNA levels in
patients hospitalized for ADHF, it did not correlate with the clinical endpoints ana-
lysed with6Ct values.PP-066
The Relationship between Heart Failure Stage/Symptom Class and Anxiety
Etem Çelik1, Serkan Çay1, Sani Murat2, Fatih Öksüz1, Tayyar Cankurt1,
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Background: Anxiety disorders are most common encountered psychiatric disorders.
There is no data regarding the relationship between this widely seen situation and
heart failure stage/symptom class.
Aim: The aim of this study is to evaluate the relationship between various stages of
anxiety disorders and heart failure stages/symptom classes.
Methods: A total of consecutive 419 patients with a mean age of 57.914.4 years
(age range, 18-96 years) admitted with the symptoms of heart failure and/or with risk
factors for heart failure were included in the study. Beck's anxiety inventory including
21 evaluation sentences was applied to all study participants to measure the level and
severity of anxiety symptoms of persons. Measured total scores were used to grade the
severity as minimal, mild, moderate, and severe.
Results: Two hundred and nineteen patients (52.3%) were male, 247 (58.9%) had
hypertension, 139 (33.2%) had diabetes, and 248 cases (59.2%) had coronary heart
disease. Stage A heart failure was present in 113 patients (27.0%), stage B in 119
patients (28.4%), stage C in 116 patients (27.7%), and stage D in remaining 71 cases
(16.9%). With regard to NYHA classiﬁcation, 228 patients (54.4%) had class I
symptoms, 101 (24.1%) had class II symptoms, 31 (7.4%) had class III symptoms, and
class IV symptoms were found in remaining 59 patients (14.1%). The mean left
ventricular ejection fraction of all population was 54.2%  12.4 and the mean Beck's
anxiety score was 13.49.0. Neither heart failure stages nor symptom classes were
found to be statistically different among 4 study groups regarding anxiety scores and
severity (all p>0.05) (table).
Conclusıon: There was no association between heart failure stage/class and anxiety
score/severity in a wide population of heart failure patients.ERS C107
